<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3247">
  <stage>Registered</stage>
  <submitdate>25/07/2011</submitdate>
  <approvaldate>25/07/2011</approvaldate>
  <nctid>NCT01403077</nctid>
  <trial_identification>
    <studytitle>480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions</studytitle>
    <scientifictitle>A Safety Assessment of the 480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo SFA Lesions</scientifictitle>
    <utrn />
    <trialacronym>STANCE</trialacronym>
    <secondaryid>AVI-SFA2011-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Superficial Femoral Artery Lesions</healthcondition>
    <healthcondition>Atherosclerosis of Femoral Artery</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - 480 Biomedical Bioresorbable Scaffold System

Experimental: Scaffold Treatment - 


Treatment: devices: 480 Biomedical Bioresorbable Scaffold System
480 Biomedical Bioresorbable Scaffold System

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Major adverse events at 6 months post procedure</outcome>
      <timepoint>6 Months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major adverse events at 1 month post procedure</outcome>
      <timepoint>1 Month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major adverse events at 3, 12 months and 24 months post procedure</outcome>
      <timepoint>3, 12 &amp; 24 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patency in the treated vessel at 1, 3, 6, 12 and 24 months post procedure</outcome>
      <timepoint>1, 3, 6, 12, 24 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Rutherford Becker Category at 1, 3, 6,12 and 24 months post procedure</outcome>
      <timepoint>1, 3, 6, 12, 24 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Walking Impairment Questionnaire</outcome>
      <timepoint>1, 3, 6, 12, 24 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ankle-Brachial Index (ABI) at 1, 3, 6, 12, and 24 months post procedure</outcome>
      <timepoint>1, 3, 6, 12, 24 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically driven TLR at 3, 12 and 24 months post procedure</outcome>
      <timepoint>3,12, 24 Months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age &gt;/= 18 years

          2. De novo stenotic lesion(s) in the superficial femoral artery located at least 1cm
             distal to the femoral bifurcation and &gt; 3 cm above the knee joint

          3. Lifestyle-limiting claudication defined as symptomatic subjects with Rutherford Becker
             Category 2-3

          4. Target lesion native reference vessel diameter 4.6 - 6.0 mm by on-line QVA; target
             lesion native reference vessel diameter less than 5.0 mm only if lesion residual
             stenosis is = 25%

          5. Lesion length: up to a maximum that can be covered by one 100mm scaffold

          6. Target lesion &gt; 50% stenosis or total occlusion

          7. Undisturbed flow to the foot via at least 2 patent infrapopliteal vessel on the
             treated side with one vessel free from &gt; 50% stenosis to the ankle joint

          8. Patent common and external iliac; TASC A &amp; B lesions may be successfully treated (&lt;30%
             residual stenosis) at the time of the index procedure

          9. The study patient or the study patient's legal representative has been informed of the
             nature of the study, agrees to its provisions and has provided written informed
             consent as approved by the Human Research Ethics Committee (HREC) of the respective
             clinical site

         10. The study patient agrees to comply with all required post-procedure follow-up visits</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Previously implanted stent(s) or stent graft(s) in the target lesion

          2. Previous endovascular treatment of the target lesion

          3. Femoral access in the target limb within 30 days of study procedure

          4. Target lesion residual stenosis &gt; 30% after pre-dilatation with nominally sized
             balloon

          5. Severely calcified lesions as determined by a balloon deformity during dilatation with
             a nominally sized balloon inflated at nominal pressure.

          6. Acute embolic complication at the trifurcation following pre-dilatation not resolved
             by aspiration

          7. Target vessel contains acute thrombus

          8. Aneurysm in target vessel

          9. Critical limb ischemia defined as Rutherford-Becker Category 4-6

         10. Intolerance, or allergies which cannot be adequately pre-medicated, to the following:
             aspirin, clopidogrel or ticlopidine, heparin, any scaffold components, contrast agents

         11. Life expectancy of less than 12 months

         12. Pregnancy or breast feeding (negative pregnancy test within 7 days required in females
             of child bearing potential)

         13. Non-atherosclerotic lesion (e.g. vasculitis or Berger's disease)

         14. Renal insufficiency (serum creatinine level &gt; 220 Âµmol/L, or subject is on dialysis)

         15. Immunocompromised

         16. Active systemic infection or lower limb infection of any nature

         17. WBC &lt; 3,000 cells/mm3

         18. Myocardial infarction within the past 1 month

         19. Stroke within 3 months

         20. Un-controlled Atrial-Fibrillation

         21. Currently participating in an investigational drug or another device study. Note:
             Trials requiring extended follow-up for products that were investigational, but have
             since become commercially available, are not considered investigational trials</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>46</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Alfred - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rosenheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>480 Biomedical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an initial evaluation of the 480 Biomedical Bioresorbable Scaffold System for the
      treatment of subjects with de novo native superficial femoral artery lesions.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01403077</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>